AGENDA

7:15 am  Registration and breakfast
8:00 am  Opening Remarks  Dr. Lawrence A. Leiter

Updates in Glycemic Control
8:10 am  National and international guideline updates  Dr. Amir K. Hanna
8:30 am  Individualizing therapy in 2016-2017  Dr. Ronald M. Goldenberg
8:50 am  The dance of two devils: Hypoglycemia and cardiovascular risk  Dr. Subodh Verma
9:10 am  Q&A / Panel Discussion

9:40 am  Health Break

Cardiovascular Safety Trials in Type 2 Diabetes
10:10 am  Completed and ongoing trials with DPP-4 inhibitors  Dr. Lawrence A. Leiter
10:30 am  Completed and ongoing trials with SGLT2 inhibitors  Dr. Bernard Zinman
10:50 am  Completed and ongoing trials with GLP-1 receptor agonists  Dr. Lawrence A. Leiter
11:10 am  Explaining the benefits of SGLT2 inhibitors and GLP-1 receptor agonists  Dr. Subodh Verma
11:30 am  Q&A / Panel Discussion

Plenary Lecture #1
12:00 pm  Interleukins and Diabetes: Why should I care?  Dr. Paul M. Ridker
12:30 pm  Q&A
12:45 pm  Lunch

Plenary Lecture #2
1:30 pm  Keeping up with a moving BP target  Dr. Philip A. McFarlane
2:00 pm  Q&A

New Clinical Trial Evidence for Special Groups
2:15 pm  The diabetic kidney  Dr. David Z. I. Cherney
2:35 pm  Obesity treatment: does it move the dial with respect to cardiovascular risk?  Dr. Marie-France Langlois
2:55 pm  Front and centre with diabetic dyslipidemia  Dr. Robert A. Hegele
3:15 pm  Q&A / Panel Discussion
3:45 pm  Closing Remarks  Dr. Subodh Verma